AI Takeaway
Thermo Fisher Scientific delivered solid FY2025 growth with revenue rising 3.9% to $44.6B and net income up 5.8% to $6.7B, while a significant acquisition drove a 26.1% increase in long-term debt and a 145.7% surge in cash balances.
Revenue
$44.56B
++3.91% YoY
EPS (Basic)
$17.77
++7.18% YoY
Operating Income
$7.75B
++5.57% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-K filing
Total revenue grew 3.9% year-over-year to $44.6B in FY2025 (from $42.9B in the prior year), reflecting continued demand across Thermo Fisher's diversified life sciences and analytical instruments portfolio. Operating income grew at a faster pace of 5.6% to $7.7B, indicating improving operational leverage.
Source: Source: 10-K Income Statement
Operating margin improved modestly by approximately 27 basis points to 17.4% in FY2025, even as SG&A expenses rose 1.6% to $8.7B. The company managed to expand profitability while absorbing higher selling and administrative costs, suggesting disciplined cost management.
Source: Source: 10-K Income Statement & Key Ratios
Total assets surged 13.4% to $110.3B, driven in part by a 29.7% increase in current assets and a 145.7% jump in cash to $9.9B. Long-term debt rose 26.1% to $39.2B, suggesting the company undertook significant financing activity, likely related to an acquisition or strategic investment.
Source: Source: 10-K Balance Sheet
2 more insights available
Upgrade to unlockLong-term debt increased 26.1% to $39.2B in FY2025, significantly raising Thermo Fisher's financial leverage. Higher debt levels increase interest expense obligations and reduce financial flexibility, particularly if operating cash flows face headwinds. The debt-to-equity ratio has risen materially, which could constrain future capital allocation.
Source: Source: 10-K Balance Sheet
Unlock 4 more detailed risk analysis
Upgrade to unlockReported EPS of $6.57 versus the $6.51 analyst consensus — a +0.9% beat for FY2025.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $44.56B | $42.88B | +3.91% |
Operating Income | $7.75B | $7.34B | +5.57% |
Net Income | $6.7B | $6.34B | +5.77% |
EPS (Basic) | $17.77 | $16.58 | +7.18% |
EPS (Diluted) | $17.74 | $16.53 | +7.32% |
R&D Expense | $1.4B | $1.39B | +0.50% |
SG&A Expense | $8.73B | $8.6B | +1.59% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $110.34B | $97.32B | +13.38% |
Current Assets | $28.71B | $22.14B | +29.68% |
Current Liabilities | $15.19B | $13.33B | +13.93% |
Stockholders' Equity | $53.41B | $49.58B | +7.71% |
Cash & Equivalents | $9.85B | $4.01B | +145.75% |
Long-Term Debt | $39.17B | $31.07B | +26.07% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $7.82B | $8.67B | -9.80% |
Investing Cash Flow | $-4.05B | $-5.84B | +30.71% |
Financing Cash Flow | $1.8B | $-6.79B | +126.52% |
Share Buybacks | $3B | $4B | -25.00% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | 17.4% | 17.1% | +0.27% |
Net Margin | 15.0% | — | — |
ROE | 12.6% | — | — |
ROA | 6.1% | — | — |
Current Ratio | $1.89 | — | — |
Other companies in Life Sciences Tools & Services
Thermo Fisher Scientific reported FY2025 revenue of $44.6B, up 3.9% year-over-year, with net income rising 5.8% to $6.7B and diluted EPS growing 7.3% to $17.74. Operating margin improved slightly to 17.4%, reflecting disciplined cost management across the business.
Thermo Fisher's long-term debt surged 26.1% to $39.2B in FY2025, while financing cash flow swung from -$6.8B to +$1.8B, strongly suggesting the company issued significant new debt, likely to fund a major acquisition or strategic investment. This was accompanied by a 145.7% jump in cash balances to $9.9B, consistent with debt proceeds being partially retained on the balance sheet.
Yes, TMO's diluted EPS grew 7.3% to $17.74 in FY2025, outpacing revenue growth of 3.9% and net income growth of 5.8%. The faster EPS growth reflects both improved profitability and the benefit of $3.0B in share buybacks during the year.
Thermo Fisher's operating cash flow declined 9.8% to $7.8B in FY2025 despite higher net income, suggesting working capital headwinds or other timing differences. However, the company's cash balance nearly tripled to $9.9B due to significant new debt issuance reflected in the financing cash flow swing from -$6.8B to +$1.8B.
The most notable risks from the FY2025 data include elevated financial leverage from a 26.1% rise in long-term debt to $39.2B, potential integration challenges from what appears to be a significant acquisition, and a 9.8% decline in operating cash flow that could pressure the company's ability to service debt and return capital. Additionally, R&D spending grew only 0.5%, raising questions about the pace of innovation investment relative to the company's scale.